|Bid||7.36 x 0|
|Ask||7.39 x 0|
|Day's Range||7.19 - 7.44|
|52 Week Range||3.70 - 9.29|
|Beta (3Y Monthly)||4.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.22|
Aphria (TSX:APHA) (NASDAQ:APHA) presents strong growth prospects, but is this small-cap pot stock a better investment?
NYSE-A: HEXO) is pleased to announce it has entered into a syndicated credit facility with Canadian Imperial Bank of Commerce (“CIBC”), as Sole Bookrunner, Co-Lead Arranger and Administrative Agent and Bank of Montreal as Co-Lead Arranger and Syndication Agent (together with CIBC, the “Lenders”). Under the terms of the credit facility, the Lenders will provide HEXO up to C$65 million of secured debt financing at a rate of interest that is expected to average in the mid-to-high 5% per annum range over its three-year term.
Is Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) or HEXO Corp. (TSX:HEXO) a better pot stock to buy today?
Analyzing Canopy Growth's Q3 Results(Continued from Prior Part)Margins During the third quarter, Canopy Growth (WEED) (CGC) reported a gross margin of ~12.4 million Canadian dollars, which was lower compared to 16.5 million Canadian dollars in the
Markets have been off to a roaring start this year; however, these five stocks have fared even better, including licensed cannabis producer HEXO Corp (TSX:HEXO) -- up more than 53% through the first six weeks of 2019.
Analysts' Ratings for WEED, TLRY, and APHA in February(Continued from Prior Part)Sales to grow Canopy Growth (WEED) (CGC) is scheduled to announce its third-quarter earnings on February 14 after the market closes. Canopy Growth is expected to see
Aurora Cannabis: Key Takeaways from Its Q2 Earnings(Continued from Prior Part)Gross margins fell In the second quarter, Aurora Cannabis (ACB) reported nearly 363% YoY (year-over-year) and 83% sequential sales growth. The company reported gross
Cannabis Stocks Hit Pause Last WeekWeekly performanceIn the week ending February 8, cannabis stocks ended in the red. The Horizons Marijuana Life Sciences ETF (HMMJ) fell nearly 2.8% from the closing on February 1. The Emerging Marijuana Growers
Do Cannabis Stocks Look Expensive?(Continued from Prior Part)Other cannabis companies Previously in this series, we compared four cannabis stocks’ forward EV-to-sales multiples. In this part, we’ll discuss the other five cannabis stocks.
VIVO Cannabis Inc. (TSX:VIVO) is trading with some attractive valuations at the moment, but do two other weed stocks offer more upside?
Aphria Inc. (TSX:APH)(NYSE:APH) and HEXO Corp. (TSX:HEXO) are potential takeover targets in the cannabis sector. Is one a better bet right now?
What to Expect from Canopy Growth's Q3 EarningsCanopy Growth’s upcoming earnings Canopy Growth (WEED) (CGC) is scheduled to announce its third-quarter earnings on February 14 after the market closes. The company is one of the most valuable
Curaleaf Is Up ~40% in 2019: Is There More Upside?(Continued from Prior Part)Analysts’ recommendations Of the three analysts that cover Curaleaf Holdings (CURLF), two are favoring a “strong buy,” and one is favoring a “buy.” On average,
Why Analysts Expect Tilray to Report a Loss in the Fourth QuarterTilray to report earnings According to NASDAQ, Tilray (TLRY) is set to report its fourth-quarter earnings next week, on February 12. Let’s look at analysts’ expectations for the
With proponents claiming that it can treat ailments as diverse as inflammation, pain, cancer, insomnia, anxiety, and depression, it's no surprise that it's already impacting major industries, like the $4.2 trillion wellness market. In fact, CBD is already showing up in spa, wellness and skincare industry products. ''Hemp-derived CBD has been touted in several medical studies as having a myriad of health benefits ranging from treating psoriasis, atopic dermatitis and eczema to minimizing seizures, stress, and insomnia,'' notes Forbes.
Canopy Growth's Bruce Linton Talks Next Steps for the IndustryShedding lightLast week, Canopy Growth (WEED) (CGC) CEO Bruce Linton shed light on the next phases for the cannabis industry at the Cantech Investment Conference.These insights have
In fact, analysts at Cowen say U.S. cannabis sales alone could reach $80 billion by 2030 - an increase of $5 billion from earlier estimates, and a 4% compound annual growth rate. Piper Jaffray believes the market for legal cannabis could be worth $15 billion to $50 billion a year, with global sales growing to $250 billion to $500 billion. Corporate America is quickly waking up to the opportunity with alcohol companies taking a stake in cannabis stocks.
Mugglehead believes the cannabis industry will look very different a year from now. Meanwhile, with hemp-derived cannabidiol (CBD) now being permitted federally, the U.S. market could also see a whole new wave of cannabis products. One of the biggest stocks in the space, Tilray is looking to make a big splash in the beverages market.
Marijuana Legalization Gets Support from Presidential CandidatesCannabis industry As the world watched Canada legalize marijuana for recreational purposes in October, some critics thought that legalization was a mistake. Marijuana has often been
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in HEXO Corp. Read More...
Hexo Corp (TSX:HEXO) has decided to focus on novel segments of the cannabis market, providing a compelling competitive edge.